<DOC>
	<DOC>NCT00955617</DOC>
	<brief_summary>This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.</brief_summary>
	<brief_title>DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Female or male, aged ≥ 18 years Patient suffering from Peripheral Arterial Occlusive Disease (PAOD) stage II or III. Patients with severely impaired renal function with an eGFR (MDRD) &lt; 50ml/min (eGFR based on recent serum creatinine and MDRD formula younger than 21 days). Patient planned to undergo therapeutic intervention in the vessels of interest between the two MRA procedures. Patient who had a major cardiovascular event within 30 days prior to the inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Dotarem</keyword>
	<keyword>Gadovist</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>MRA</keyword>
</DOC>